A system establishing compatibility profiles for artificial oxygen carriers and other substances

被引:4
作者
Dinkelmann, S
Röhlke, W
Meinert, H
Northoff, H
机构
[1] Inst Transfus Med, D-72076 Tubingen, Germany
[2] Univ Ulm, AG Chem Biokompatibler Verbindungen, D-89069 Ulm, Germany
来源
ARTIFICIAL CELLS BLOOD SUBSTITUTES AND IMMOBILIZATION BIOTECHNOLOGY | 2001年 / 29卷 / 01期
关键词
D O I
10.1081/BIO-100001256
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Worldwide, great efforts are being made to develop a clinically useful artificial oxygen carrier. Toxicological and immunological compatibility is generally tested using animal experiments but inflammatory parameters in particular show large species-specific differences. Therefore, we developed an in vitro system using human components to establish a compatibility profile of unknown compounds. The test system comprises induction of hemolysis, activation of complement (C3a), induction/suppression of cytokine production, influence on cell proliferation, direct toxicity on peripheral leukocytes, and phagocytosis of the material under test and of microbes. The test system will be described, along with results of various perfluorocarbon emulsions. When testing lecithin-based perfluorodecalin (PFD) emulsions, and comparing them to Pluronic-based PFD emulsions, we could show that Pluronic-based emulsions were virtually untoxic to peripheral human leukocytes. They neither inhibited cell proliferation nor caused any hemolysis, but caused mild to moderate inhibition of endotoxin-induced cytokine production. At the same time, lecithin-based PFD emulsion caused substantial cytotoxicity in phagocytic cells like monocytes (60-100% after 24 h incubation) and granulocytes (10-20% after 24 h incubation). They also suppressed endotoxin-induced cytokine production in monocytes to more than 98% and inhibited cell proliferation of an endothelial (ECV 304) and a monocytic cell line (MonoMac6) to more than 95%.
引用
收藏
页码:57 / 70
页数:14
相关论文
共 15 条
[1]   LIMITATION OF MYOCARDIAL REPERFUSION INJURY BY INTRAVENOUS PERFLUOROCHEMICALS - ROLE OF NEUTROPHIL ACTIVATION [J].
BAJAJ, AK ;
COBB, MA ;
VIRMANI, R ;
GAY, JC ;
LIGHT, RT ;
FORMAN, MB .
CIRCULATION, 1989, 79 (03) :645-656
[2]   Effects of a novel perfluorocarbon emulsion on neutrophil chemiluminescence in human whole blood in vitro [J].
Edwards, CM ;
Lowe, KC ;
Rolke, W ;
Geister, U ;
Reuter, P ;
Meinert, H .
ARTIFICIAL CELLS BLOOD SUBSTITUTES AND IMMOBILIZATION BIOTECHNOLOGY, 1997, 25 (03) :255-260
[3]   PHARMACOLOGICAL PERTURBATION OF NEUTROPHILS BY FLUOSOL RESULTS IN A SUSTAINED REDUCTION IN INFARCT SIZE IN THE CANINE MODEL OF REPERFUSION [J].
FORMAN, MB ;
PITARYS, CJ ;
VILDIBILL, HD ;
LAMBERT, TL ;
INGRAM, DA ;
VIRMANI, R ;
MURRAY, JJ .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1992, 19 (01) :205-216
[4]   FLUOSOL-DA AS A RED-CELL SUBSTITUTE IN ACUTE ANEMIA [J].
GOULD, SA ;
ROSEN, AL ;
SEHGAL, LR ;
SEHGAL, HL ;
LANGDALE, LA ;
KRAUSE, LM ;
RICE, CL ;
CHAMBERLIN, WH ;
MOSS, GS .
NEW ENGLAND JOURNAL OF MEDICINE, 1986, 314 (26) :1653-1656
[5]  
Habler O, 1999, ZBL CHIR, V124, P260
[6]   PRESERVATION OF LEFT-VENTRICULAR EJECTION FRACTION DURING PERCUTANEOUS TRANS-LUMINAL CORONARY ANGIOPLASTY BY DISTAL TRANSCATHETER CORONARY PERFUSION OF OXYGENATED FLUOSOL DA 20-PERCENT [J].
JAFFE, CC ;
WOHLGELERNTER, D ;
CABIN, H ;
BOWMAN, L ;
DECKELBAUM, L ;
REMETZ, M ;
CLEMAN, M .
AMERICAN HEART JOURNAL, 1988, 115 (06) :1156-1164
[7]  
KAUFMAN RJ, 1994, ARTIFICIAL CELLS BLO, V22, pA112
[8]   USE OF OXYGENT(TM), A PERFLUOROCHEMICAL-BASED OXYGEN CARRIER, AS AN ALTERNATIVE TO INTRAOPERATIVE BLOOD-TRANSFUSION [J].
KEIPERT, PE .
ARTIFICIAL CELLS BLOOD SUBSTITUTES AND IMMOBILIZATION BIOTECHNOLOGY, 1995, 23 (03) :381-394
[9]   DEVELOPMENT AND CLINICAL-APPLICATION OF PERFLUOROCHEMICAL ARTIFICIAL BLOOD [J].
OHYANAGI, H ;
SAITOH, Y .
INTERNATIONAL JOURNAL OF ARTIFICIAL ORGANS, 1986, 9 (05) :363-368
[10]  
OHYANAGI H, 1995, ARTIFICIAL RED CELLS, P199